Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.30 |
| ▸ | PPARG | P37231 | 2/20 | 0.30 |
| ▸ | PTGES | O14684 | 2/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7668090 | 0.79 | GAA (0.33) | CYP1A2 | |
| SCHEMBL5722637 | 0.75 | DRD2 (0.33) | — | |
| SCHEMBL7930742 | 0.73 | DRD2 (0.31) | — | |
| SCHEMBL7935001 | 0.73 | DRD2 (0.31) | — | |
| SCHEMBL10711696 | 0.69 | KDM4E (0.41) | NAAATDP1BCHEALOX5PPARG | |
| SCHEMBL7930592 | 0.68 | LTA4H (0.35) | — | |
| SCHEMBL10711233 | 0.68 | KDM4E (0.42) | NAAATDP1BCHEALOX5PPARG | |
| SCHEMBL10707863 | 0.67 | KDM4E (0.40) | NAAATDP1BCHEALOX5PPARG | |
| SCHEMBL10707654 | 0.66 | KDM4E (0.41) | TDP1BCHEALOX5PPARGPTGES | |
| SCHEMBL10710322 | 0.66 | KDM4E (0.41) | TDP1BCHEALOX5PPARGPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944690-B1 | 1,1,5,7-TETRAFLUORO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES AND THEIR USE IN LIQUID CRYSTAL MIXTURES | AVENTIS RES & TECH GMBH & CO (DE) | 2001-11-28 | — | — | EP | disclosed |